BlackRock’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-2,869,885
| Closed | -$278M | – | 5133 |
|
|
2019
Q3 | $278M | Buy |
2,869,885
+113,605
| +4% | +$11.4M | 0.01% | 1153 |
|
|
2019
Q2 | $282M | Sell |
2,756,280
-186,616
| -6% | -$20.1M | 0.01% | 1169 |
|
|
2019
Q1 | $335M | Sell |
2,942,896
-163,402
| -5% | -$12M | 0.02% | 1033 |
|
|
2018
Q4 | $122M | Buy |
3,106,298
+75,255
| +2% | +$3.26M | 0.01% | 1666 |
|
|
2018
Q3 | $165M | Buy |
3,031,043
+161,811
| +6% | +$11.1M | 0.01% | 1616 |
|
|
2018
Q2 | $237M | Buy |
2,869,232
+229,786
| +9% | +$17.7M | 0.01% | 1335 |
|
|
2018
Q1 | $176M | Sell |
2,639,446
-10,812
| -0.4% | -$624K | 0.01% | 1462 |
|
|
2017
Q4 | $136M | Buy |
2,650,258
+35,801
| +1% | +$2.57M | 0.01% | 1655 |
|
|
2017
Q3 | $233M | Buy |
2,614,457
+560,723
| +27% | +$42.6M | 0.01% | 1224 |
|
|
2017
Q2 | $123M | Buy |
2,053,734
+213,520
| +12% | +$11.9M | 0.01% | 1667 |
|
|
2017
Q1 | $98.2M | Buy |
1,840,214
+1,824,117
| +11,332% | +$108M | 0.01% | 1792 |
|
|
2016
Q4 | $804K | Buy |
16,097
+3,574
| +29% | +$191K | ﹤0.01% | 1568 |
|
|
2016
Q3 | $753K | Buy |
12,523
+10,824
| +637% | +$624K | ﹤0.01% | 1606 |
|
|
2016
Q2 | $87K | Buy |
1,699
+1,202
| +242% | +$51.4K | ﹤0.01% | 2625 |
|
|
2016
Q1 | $15K | Buy |
497
+327
| +192% | +$10.3K | ﹤0.01% | 2993 |
|
|
2015
Q4 | $8K | Hold |
170
| – | – | ﹤0.01% | 3007 |
|
|
2015
Q3 | $7K | Hold |
170
| – | – | ﹤0.01% | 2910 |
|
|
2015
Q2 | $10K | Sell |
170
-32,807
| -99% | -$2.17M | ﹤0.01% | 2817 |
|
|
2015
Q1 | $2.56M | Buy |
+32,977
| New | +$1.9M | ﹤0.01% | 1020 |
|
BlackRock's ONCE Position: Q4 2019 in Review
BlackRock sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 2,869,885 shares — an estimated $278M sold.
BlackRock first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $335M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- BlackRock reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- BlackRock sold 2,869,885 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $278M.
- BlackRock first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- BlackRock's Spark Therapeutics, Inc. Common Stock position peaked at $335M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on BlackRock's 13F filing for Q4 2019, filed 13 Feb 2020.